Financial Data and Key Metrics Changes - Total revenue for the quarter was $16.6 million, a decrease of approximately 3% compared to $17 million in the prior year period [11] - Core study revenue reached a record $16.6 million, representing growth of approximately 32% from $12.6 million in the year-ago period [11] - Adjusted EBITDA for the quarter was $575,000, marking the third consecutive quarter of positive adjusted EBITDA [13] - GAAP loss from operations for the quarter was approximately $275,000 [13] - Gross margin for the quarter was 47%, down from 61% in the prior year period [13] Business Line Data and Key Metrics Changes - The core translational oncology services platform demonstrated strong performance, with record services revenue driven by effective study execution and conversion of previously booked work [3][11] - Data revenue was not recognized in the third quarter, compared to $4.5 million in the prior year period, contributing to the overall year-over-year revenue decline [12] - The company anticipates that data revenue will become a more meaningful contributor over time as the platform develops [12] Market Data and Key Metrics Changes - The company noted that customer budgets are stabilizing, leading to improved bookings converting into revenue [3] - There is a healthy underlying demand for the company's services, with expectations for revenue normalization as studies progress [4] Company Strategy and Development Direction - The company is focused on balancing growth and investment while maintaining positive adjusted EBITDA [5] - Investments are being made in both the data platform and the therapeutic subsidiary, Corellia, without diluting shares [5][9] - The company aims to maximize shareholder value across its differentiated tumor bank, radiopharmaceutical capabilities, and therapeutic subsidiary [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year revenue growth and positive adjusted EBITDA while continuing to invest in growth drivers [5][10] - The company expects to see the payoff from current investments beginning in fiscal 2027, with more meaningful acceleration anticipated in fiscal 2028 [5][10] - Discussions regarding external funding for Corellia are ongoing, with positive feedback from potential partners [8][9] Other Important Information - The company ended the quarter with $7.1 million in cash and no debt, maintaining a cash balance within projected ranges [16] - Operating expenses increased to $7.2 million, reflecting strategic investments in R&D, sales, and marketing [15] Q&A Session Summary - There were no questions from participants during the Q&A session [17]

Core Viewpoint - Defence Therapeutics Inc. is launching a private placement to raise up to $11,000,000 through the issuance of 20,000,000 units at a price of $0.55 per unit, each consisting of one common share and one warrant [1] Group 1: Private Placement Details - The private placement aims to raise aggregate gross proceeds of $6,000,000 (CAD) from two institutional investors, with proceeds deposited in escrow prior to closing [2] - Upon closing, the units will be released from escrow, and the investors' proceeds will be provided to the company in monthly cash tranches of $333,333 (CAD) over an 18-month period [2][3] - The company will release shares in equal monthly installments of approximately 606,060 shares over the 18-month term, contingent upon cash payments [3] Group 2: Warrant and Fee Structure - A total of 10,909,091 warrants will be issued, exercisable at $0.65 (CAD) per share for 24 months, with an equity blocker provision limiting ownership to 9.99% of outstanding shares [4] - Investors will receive a corporate finance fee of $360,000 (CAD), payable in cash or through the issuance of 654,546 units at the private placement price [5] Group 3: Use of Proceeds - The proceeds from the private placement will be utilized to advance the company's Antibody Drug Conjugate (ADC) and Radiopharmaceutical programs, develop partnerships, and for working capital [6] Group 4: Regulatory and Compliance Information - All securities issued under the private placement will be subject to resale restrictions in accordance with Canadian securities laws, with the closing expected around March 6, 2026, pending CSE approval [7]